FILING ANALYSIS · FRIDAY, NOVEMBER 13
Tvardi Therapeutics, Inc. TVRD — 8-K: Results of Operations and Financial Condition
neutral
The company's third-quarter results show increased research and development expenses and a net loss of $6.1 million, with cash and cash equivalents of $22.3 million expected to fund operations into the third quarter of 2027. Advancement of TTI-109 into ulcerative colitis and other indications is subject to additional funding and IND clearance.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →